Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Last trade$0.6611
Day change-$0.0321 (-4.63%)
Day range$0.656 – $0.717
Volume549,011
Market cap$43M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$42.77M
Price / earnings
—
Price / book
0.34×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.17×
Profitability
Earnings per share
-$1.46
Return on assets
-53.19%
Return on equity
-71.36%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.05×
Quick ratio
8.05×
Cash ratio
1.48×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$66.79M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PLRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$7.81M
$7.14M
$8.19M
$7.99M
$10.33M
$13.39M
$15.5M
$14.53M
Research and development
$17.93M
$16.73M
$13.58M
$15.59M
$17.94M
$32.2M
$43.44M
$38.79M
Total operating expenses
$25.74M
$23.86M
$21.77M
$23.58M
$28.27M
$45.59M
$58.94M
$53.32M
Operating income
-$25.74M
-$23.86M
-$21.77M
-$23.58M
-$28.27M
-$45.59M
-$58.94M
-$53.32M
Interest expense
$0
$0
$0
-$136K
-$815K
-$809K
-$799K
-$834K
Income before taxes
-$24.38M
-$22.37M
-$20.04M
-$23.58M
-$26.3M
-$43.3M
-$56.17M
-$49.73M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$24.38M
-$22.37M
-$20.04M
-$23.58M
-$26.3M
-$43.3M
-$56.17M
-$49.73M
Net income attributable to common shareholders
-$24.38M
-$22.37M
-$20.04M
-$23.58M
-$26.3M
-$43.3M
-$56.17M
-$49.73M
EBITDA
-$25.51M
-$23.61M
-$21.51M
-$23.21M
-$27.83M
-$45.15M
-$58.49M
-$52.86M
Basic earnings per share
-$0.39
-$0.36
-$0.32
-$0.38
-$0.43
-$0.71
-$0.92
-$0.82
Diluted earnings per share
-$0.39
-$0.36
-$0.32
-$0.38
-$0.43
-$0.71
-$0.92
-$0.82
Recent news
Company coverage with links to the original publishers.
Pliant Therapeutics presented updated Phase 1 trial data for PLN-101095, an integrin inhibitor combined with pembrolizumab, showing encouraging results in immune checkpoint inhibitor-refractory patients. The drug demonstrated confirmed responses with 89% average tumor reduction and 19-month median time on treatment. The company has initiated a Phase 1b expansion trial with interim data expected in 2027.
Pliant Therapeutics has voluntarily paused enrollment and dosing in its ongoing BEACON-IPF Phase 2b trial of bexotegrast, leading to a significant drop in its stock price. Faruqi & Faruqi, LLP is investigating potential claims on behalf of investors who suffered significant losses.
Pliant Therapeutics has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis, following a recommendation by the trial's independent Data Safety Monitoring Board. The company will monitor current patients while the data is reviewed.
Pliant Therapeutics presented positive data from the INTEGRIS-PSC trial, showing that their drug bexotegrast improved markers and symptoms of cholestasis and stabilized liver fibrosis in patients with primary sclerosing cholangitis.
Pliant Therapeutics' Chief Business Officer Hans Hull sold 9,900 shares of the company's common stock, valued at over $114,000. The sale was part of a nondiscretionary plan to satisfy withholding tax liabilities related to the vesting of performance-vested stock units.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.